Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19332396 | 0.78 | F2RL1 (0.42) | F2RL1DGAT1NPC1 | |
| SCHEMBL23337421 | 0.78 | F2RL1 (0.40) | F2RL1DGAT1 | |
| SCHEMBL24320461 | 0.76 | F2RL1 (0.38) | F2RL1DGAT1 | |
| SCHEMBL14298916 | 0.76 | F2RL1 (0.42) | F2RL1HTTDGAT1NPC1 | |
| SCHEMBL30605723 | 0.74 | F2RL1 (0.38) | F2RL1DGAT1 | |
| SCHEMBL3174588 | 0.74 | F2RL1 (0.40) | F2RL1DGAT1 | |
| Potassium Ion SCHEMBL2147280 | 0.74 | F2RL1 (0.41) | F2RL1DGAT1NPC1 | |
| SCHEMBL13871296 | 0.73 | F2RL1 (0.35) | F2RL1DGAT1NPC1 | |
| SCHEMBL22899580 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL2647731 | 0.72 | DGAT1 (0.36) | HTTDGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | disclosed |
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| EP-1430055-B1 | 7-TERT-BUTYL-3-(2-FLUOROPHENYL)-6-(2H-¬1,2,4|TRIAZOL-3-YLMETHOXY)-¬1,2,4|TRIAZOLO¬4,3-B|PYRIDAZINE FOR THE TREATMENT OF ANXIETY AND CONVULSIONS | MERCK SHARP & DOHME (GB) | 2006-07-12 | — | — | EP | disclosed |
| US-7015224-B2 | 7-Tert-butyl-3-(2-fluorophenyl)-6-(2H-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3b) pyridazine for the treatment of anxiety and convulsions | MERCK SHARP & DOHME LTD. | 2006-03-21 | — | — | US | disclosed |
| US-20040242586-A1 | 7-Tert-butyl-3-(2-fluoropenyl)-6-(2h(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo 4,3b)pyridazine for the treatment of anxiety and convulsions | MERCK SHARP & DOHME LTD. (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1430055-A1 | 7-TERT-BUTYL-3-(2-FLUOROPHENYL)-6-(2H-[1,2,4]TRIAZOL-3-YLMETHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE FOR THE TREATMENT OF ANXIETY AND CONVULSIONS | MERCK SHARP & DOHME LTD. (GB) | 2004-06-23 | — | — | EP | disclosed |
| EP-0915875-B1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2003-04-09 | — | — | EP | disclosed |
| WO-2003024968-A1 | 7-TERT-BUTYL-3-(2-FLUOROPHENYL)-6-(2H-(1,2,4)TRIAZOL-3-YLMETHOXY)-(1,2,4)TRIAZOLO (4,3-B) PYRIDAZINE FOR THE TREATMENT OF ANXIETY AND CONVULSIONS | MERCK SHARP & DOHME LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
| US-6444666-B1 | SUCH AS ALZHEIMER'S DISEASE; SUBSTITUTED 1,2,4-TRIAZOLO(4,3-B) PYRIDAZINE DERIVATIVES ARE LIGANDS FOR GABA RECEPTORS; CONVULSANT ACTIVITY IS REDUCED OR ELIMINATED | MERCK SHARP & DOHME LTD. (GB) | 2002-09-03 | — | — | US | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6297235-B1 | ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2001-10-02 | — | — | US | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| EP-1107967-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR TREATING ANXIETY AND ENHANCING COGNITION | MERCK SHARP & DOHME LTD. (GB) | 2001-06-20 | — | — | EP | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0986562-A1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000012505-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR TREATING ANXIETY AND ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998050385-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249583-A1 | HMG-CoA reductase inhibitors | HMGCR, LDLR, PCSK9 | F2RL1 1135/4885HTT 1209/4885DGAT1 717/4885 |
| US-20040242586-A1 | 7-Tert-butyl-3-(2-fluoropenyl)-6-(2h(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo 4,3b)pyridazine for the treatment of anxiety and convulsions | GABRA3, GABRA4, GABBR1 | F2RL1 507/4885HTT 2925/4885DGAT1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.